Who are Deucrictibant high dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ICATIBANT ACETATE, Cannabis Sativa Oil, MediCabilis CBD Oil, Hemp, Cannabis oil, dl-Methylphenidate plus Cannabidiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/deucrictibant-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Deucrictibant high dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deucrictibant high dose (Deucrictibant high dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bradykinin receptor antagonist. Area: Cardiovascular.

phase 2 Bradykinin receptor antagonist B2 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Deucrictibant high dose (Deucrictibant high dose) — Pharvaris Netherlands B.V.. Deucrictibant is a bradykinin receptor 2 antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Deucrictibant high dose TARGET	Deucrictibant high dose	Pharvaris Netherlands B.V.	phase 2	Bradykinin receptor antagonist	B2 receptor
ICATIBANT ACETATE	ICATIBANT ACETATE		marketed		bradykinin B2 receptor	2008-01-01
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Hemp	Hemp	Thammasat University Hospital	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor
Cannabis oil	Cannabis oil	Assaf-Harofeh Medical Center	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bradykinin receptor antagonist class)

Pharvaris Netherlands B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Deucrictibant high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/deucrictibant-high-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing